Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: A subgroup analysis of a phase 2 study

Haematologica

Volumn 102, Issue 4, 2017, Pages e156-e159

  Salles, Gilles ^a   Schuster, Stephen J ^b   De Vos, Sven ^c   Wagner Johnston, Nina D ^d   Viardot, Andreas ^e   Blum, Kristie A ^f   Flowers, Christopher R ^g   Jurczak, Wojciech J ^h   Flinn, Ian W ⁱ   Kahl, Brad S ^j   Martin, Peter ^k   Kim, Yeonhee ^l   Shreay, Sanatan ^l   Will, Matthias ^l   Sorensen, Bess ^l   Breuleux, Madlaina ^l   Zinzani, Pier Luigi ^m   Gopal, Ajay K ⁿ  

^a UNIVERSITÉ LYON 1   (France)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e UNIVERSITY HOSPITAL ULM   (Germany)

^f THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^g EMORY UNIVERSITY   (United States)

^h JAGIELLONIAN UNIVERSITY   (Poland)

ⁱ SARAH CANNON RESEARCH INSTITUTE   (United States)

^j WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k WEILL CORNELL MEDICAL COLLEGE   (United States)

^l GILEAD SCIENCES   (United States)

^m UNIVERSITY OF BOLOGNA   (Italy)

ⁿ UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKYLATING AGENT; ASPARTATE AMINOTRANSFERASE; IDELALISIB; RITUXIMAB; ANTINEOPLASTIC AGENT; PURINE DERIVATIVE; QUINAZOLINONE DERIVATIVE;

ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; AGED; ALPHA HEMOLYTIC STREPTOCOCCUS; BLEEDING; COLITIS; COUGHING; DEATH; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FEVER; FOLLICULAR LYMPHOMA; HUMAN; LETTER; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; NECROTIZING PNEUMONIA; NEUTROPENIA; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; SEPTIC SHOCK; STREPTOCOCCUS VIRIDANS INFECTION; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; AGE; CLINICAL TRIAL; DRUG ADMINISTRATION; MIDDLE AGED; MORTALITY; PATHOLOGY; PATIENT SAFETY; RECURRENT DISEASE; RISK FACTOR; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ALKYLATING AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; PATIENT SAFETY; PURINES; QUINAZOLINONES; RECURRENCE; RISK FACTORS; RITUXIMAB; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 85016993064     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2016.151738     Document Type: Letter

References (15)

1. Glass AG, Karnell LH, Menck HR. The National Cancer Data Base report on non-Hodgkin’s lymphoma. Cancer. 1997;80(12):2311-2320.
2. Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood. 2006;107(1):265-276.
3. Lunning MA, Vose JM. Management of indolent lymphoma: where are we now and where are we going. Blood Rev. 2012;26(6):279-288.
4. Swenson WT, Wooldridge JE, Lynch CF, Forman-Hoffman VL, Chrischilles E, Link BK. Improved survival of follicular lymphoma patients in the United States. J Clin Oncol. 2005;23(22):5019-5026.
5. Tan D, Horning SJ, Hoppe RT, et al. Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience. Blood. 2013;122(6):981-987.
6. ZYDELIG® (idelalisib) tablets, for oral use. Prescribing information. Gilead Sciences, Inc. Foster City, CA, USA. 2014.
7. ZYDELIG (idelalisib tablets). Summary of Product Characteristics, Gilead Sciences International Ltd, Cambridge, UK. 2015.
8. Gopal AK, Kahl BS, de Vos S, et al. PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med. 2014; 370(11):1008-1018.
9. Czuczman MS, Fayad L, Delwail V, et al. Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study. Blood. 2012;119(16):3698-3704.
10. Tinmouth A, Zanke B, Imrie KR. Fludarabine in alkylator-resistant follicular non-Hodgkin’s lymphoma. Leuk Lymphoma. 2001;41(1-2):137-145.
11. van Oers MH, Klasa R, Marcus RE, et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular nonHodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood. 2006;108(10):3295-3301.
12. Bartlett NL, LaPlant BR, Qi J, et al. Ibrutinib monotherapy in relapsed/refractory follicular lymphoma (FL): preliminary results of a phase 2 consortium (P2C) trial. Blood. 2014;124(21):800.
13. Witzig TE, Wiernik PH, Moore T, et al. Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin’s Lymphoma. J Clin Oncol. 2009;27(32):5404-5409.
14. Casulo C, Byrtek M, Dawson KL, et al. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study. J Clin Oncol. 2015; 33(23):2516-2522.
15. Kahl BS, Bartlett NL, Leonard JP, et al. Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell nonHodgkin lymphoma: results from a Multicenter Study. Cancer. 2010; 116(1):106-114.